Answers are grounded in this paper and cite their sources.
In Defense of TNT: A Dynamite StrategyIn their critique of total neoadjuvant therapy (TNT) for rectal cancer, Drs Shi and Mamon 1 state that "there have been few randomized studies comparing TNT to current standards of care."Actually, there have been no adequately sized randomized studies comparing TNT with the older approach of neoadjuvant chemoradiation plus postoperative chemotherapy, and, as Shi and Mamon 1 correctly note, there never will be.As they further note, TNT is, and has been for many years, a fully acceptable option in NCCN guidelines and is, by definition, a standard of care.The logic and available nonrandomized data are sufficiently compelling that the NCI Gastrointestinal Steering Committee unanimously endorsed the NRG GI-002, a chemo-first TNT platform study, as the standard to which new experimental agents are investigated.
No takes yet. Share an insight, caveat, or question.
Cercek et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: